ATE389405T1 - Fexofenadine hydrochlorid polymorph - Google Patents

Fexofenadine hydrochlorid polymorph

Info

Publication number
ATE389405T1
ATE389405T1 AT02751479T AT02751479T ATE389405T1 AT E389405 T1 ATE389405 T1 AT E389405T1 AT 02751479 T AT02751479 T AT 02751479T AT 02751479 T AT02751479 T AT 02751479T AT E389405 T1 ATE389405 T1 AT E389405T1
Authority
AT
Austria
Prior art keywords
polymorpho
fexofenadine hydrochloride
polymorph
fexofenadine
hydrochloride
Prior art date
Application number
AT02751479T
Other languages
English (en)
Inventor
Frederico Junquera Milla
Original Assignee
Texcontor Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texcontor Ets filed Critical Texcontor Ets
Application granted granted Critical
Publication of ATE389405T1 publication Critical patent/ATE389405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02751479T 2001-07-31 2002-07-29 Fexofenadine hydrochlorid polymorph ATE389405T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01610081 2001-07-31

Publications (1)

Publication Number Publication Date
ATE389405T1 true ATE389405T1 (de) 2008-04-15

Family

ID=8183555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751479T ATE389405T1 (de) 2001-07-31 2002-07-29 Fexofenadine hydrochlorid polymorph

Country Status (7)

Country Link
US (2) US20040248935A1 (de)
EP (1) EP1414453B1 (de)
AT (1) ATE389405T1 (de)
DE (1) DE60225694T2 (de)
ES (1) ES2301662T3 (de)
PT (1) PT1414453E (de)
WO (1) WO2003011295A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009259A (es) * 2001-04-09 2004-06-03 Teva Pharma Polimorfos de clorhidrato de fexofenadina.
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1623985A (zh) * 1994-05-18 2005-06-08 阿温蒂斯药物公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate

Also Published As

Publication number Publication date
DE60225694T2 (de) 2008-06-26
EP1414453B1 (de) 2008-03-19
WO2003011295A1 (en) 2003-02-13
WO2003011295B1 (en) 2003-04-03
US20040248935A1 (en) 2004-12-09
PT1414453E (pt) 2008-05-29
EP1414453A1 (de) 2004-05-06
DE60225694D1 (de) 2008-04-30
ES2301662T3 (es) 2008-07-01
US20100010229A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
GB0124627D0 (en) Novel compounds
MXPA05009367A (es) Antagonistas del receptor opioide.
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
ATE372767T1 (de) Dpp-iv-hemmer
DK1220842T3 (da) Cyklisk aminforbindelse som CCR5-antagonist
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
DE60302157D1 (de) Opioidrezeptorantagonisten
SE0201544D0 (sv) Novel compounds and thier use
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
SE0101932D0 (sv) Pharmaceutical combinations
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
NO20054787L (no) Indenderivater som farmasotiske midler
EA200801199A1 (ru) Ингибиторы киназы
IL166483A0 (en) Pharmaceutical compositions containing ciclesonideand an antihistamine
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
WO2003037916A3 (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414453

Country of ref document: EP

REN Ceased due to non-payment of the annual fee